JASWANT PUROHIT: Open Payments
NPI 1437169786 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$712 in 22 payments from 8 companies in 2025. Trend: 2023 $141 · 2024 $151 · 2025 $712
Food & beverage: $712
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $185 |
| Janssen Pharmaceuticals, Inc | 2 | $131 |
| Neurocrine BioSciences, Inc. | 1 | $124 |
| Vanda Pharmaceuticals Inc. | 5 | $113 |
| Luye Pharma (USA) Ltd. | 1 | $71 |
| Alkermes, Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
Products named: COBENFY, INVEGA SUSTENNA, INGREZZA, FANAPT, ERZOFRI EXTENDED-RELEASE, ARISTADA, ABILIFY MAINTENA, UZEDY.
Industry payments across MI — which companies pay providers there.
